Exploring New Modalities for Enhanced Efficacy and Convenience

By Emmanuel David

When it comes to HIV treatment, the landscape is constantly evolving, driven by the pursuit of enhanced efficacy, convenience, and reduced side effects. Recent years have witnessed alot of advancements, with the coming up of novel treatment modalities targeted to transform the way we approach HIV care. Among these innovations, long-acting injectable antiretroviral therapy (ART) has emerged as a promising avenue, offering potential benefits in simplifying treatment regimens and improving adherence rates.

Long-acting injectable ART represents a paradigm shift in HIV management, addressing longstanding challenges associated with daily pill regimens. Traditional oral ART requires strict adherence to daily dosing schedules, which can be burdensome for patients and increase the risk of treatment failure due to missed doses. In contrast, long-acting injectable formulations offer extended drug release, allowing for less frequent dosing intervals ranging from once monthly to once every few months. This does not only reduces the pill burden but also enhances convenience and improve adherence rates among individuals living with HIV.

The appeal of long-acting injectable ART lies not only in its convenience but also in its potential to mitigate drug resistance and treatment fatigue. By providing sustained plasma drug levels, these formulations may help prevent viral replication and minimize the emergence of drug-resistant strains. Moreover, for patients experiencing treatment fatigue or challenges with adherence, the prospect of fewer clinic visits and reduced pill-taking may reinvigorate engagement with HIV care, leading to better health outcomes in the long term.

Research into novel drug classes and mechanisms of action further enriches HIV treatment options, offering hope for individuals facing treatment challenges. From next-generation integrase inhibitors to innovative immune-based therapies, the pipeline of experimental agents continues to expand, driven by a deepening understanding of HIV pathogenesis and therapeutic targets. These novel approaches not only aim to enhance treatment efficacy but also to address specific issues such as drug resistance, comorbidities, and long-term toxicity.

However, as with any medical innovation, the translation of these promising modalities from clinical trials to real-world practice necessitates careful consideration of various factors. Beyond efficacy and safety, factors such as cost, accessibility, and patient preferences play an important roles in shaping the adoption and implementation of new treatment strategies. Moreover, ongoing efforts are needed to ensure equitable access to these innovations, particularly in resource-limited settings where the burden of HIV remains disproportionately high.

In conclusion, the emergence of new treatment modalities in HIV care represents a watershed moment in the fight against the epidemic. Long-acting injectable ART, alongside other innovative approaches, holds the promise of revolutionizing HIV treatment by offering enhanced efficacy, convenience, and reduced side effects. As research continues to advance and new therapies reach the clinic, the outlook for individuals living with HIV is increasingly hopeful, underscoring the transformative power of scientific innovation in improving health outcomes and quality of life.

Embracing Diversity: Celebrating LGBTQI+ Identities

By: Titiloye Olajuwon Paulina

In a world marked by diversity, the LGBTQI+ community stands as a vibrant tapestry of identities, experiences, and voices. From the struggles of the past to the triumphs of the present, the journey towards acceptance and equality continues to shape our society. Each letter in the LGBTQI+ spectrum represents a unique facet of human identity, reminding us that love knows no bounds and authenticity knows no limits.

It’s crucial to recognize that LGBTQI+ individuals deserve the same rights, respect, and opportunities as anyone else. Embracing diversity means creating inclusive spaces where everyone feels valued and empowered to live authentically. It’s about challenging stereotypes, dismantling prejudice, and advocating for equality in all aspects of life.

As allies, it’s our responsibility to amplify LGBTQI+ voices, uplift their stories, and stand alongside them in the fight for justice and equality. Together, we can create a world where love, acceptance, and celebration reign supreme, where every individual can live proudly and freely as their authentic selves. Let’s embrace diversity, celebrate LGBTQI+ identities, and build a future where everyone is truly seen, heard, and loved.

UNDERSTANDING THE INTERSECTION: Transgender Rights and HIV/AIDS in NIGERIA

By: Nuchi Nweneka

Nigeria, like many other countries, faces significant challenges in addressing the needs and rights of the transgender community. Discrimination, stigma and lack of legal recognition contribute to a hostile environment for transgender individuals, impacting various aspects of our lives, including healthcare access.

Here we explore the intersection of transgender rights and HIV/AIDS in Nigeria, shedding light on the unique challenges faced by the transgender community and how these issues contribute to new HIV infections.

Challenges Faced by the Transgender Community in Nigeria:

The transgender community in Nigeria grapples with widespread discrimination, violence and social exclusion. Legal barriers prevent transgender individuals from accessing gender-affirming healthcare and legal recognition, leading to a lack of access to essential services. This marginalization pushes many transgender individuals into vulnerable situations, including engaging in risky behaviors that increase their susceptibility to HIV infection.

The lack of access to healthcare, including HIV testing, prevention, and treatment services, exacerbates the risk of new infections among transgender individuals in Nigeria. Stigma and discrimination further deter transgender individuals from seeking help, leading to undiagnosed cases and untreated infections. Additionally, the intersection of poverty, homelessness and limited employment opportunities among transgender individuals amplifies their vulnerability to HIV/AIDS.

To combat the rising rates of HIV infections among transgender individuals in Nigeria, a multi-faceted approach is indeed. This includes advocating for legal reforms to protect transgender rights, increasing access to gender-affirming healthcare services, implementing comprehensive HIV prevention and treatment programs tailored to the transgender community and promoting education and awareness to reduce stigma and discrimination.

The challenges faced by the transgender community in Nigeria have far-reaching implications for HIV/AIDS rates in the country. By addressing the systemic barriers etc. that impact transgender individuals, we hope to create a more inclusive and supportive environment that promotes health and well-being for all. It is crucial to advocate for policies and programs that prioritize the rights and needs of the transgender community to effectively combat new HIV infections and promote overall public health in Nigeria.

Driving Progress in the Fight Against HIV/AIDS

Driving Progress in the Fight Against HIV/AIDS

By David Emmanuel

In the ongoing battle against HIV/AIDS, clinical trials stand as a pillar of hope, driving progress in prevention, treatment, and importantly for the eradication of the epidemic. With each milestone achieved and every breakthrough discovered, we get closer to the goal of ending HIV/AIDS and ushering in a future free from its devastating impact.

At the heart of HIV clinical trials is a spirit of innovation, as researchers continually push the boundaries of science to develop new and improved prevention and treatment modalities. From anti-retroviral therapy to innovative vaccine. the landscape of HIV research is characterized by a relentless pursuit of novel approaches to combat the virus. These groundbreaking advancements not only offer hope to individuals living with HIV but also hold promise in preventing new infections and reducing the global burden of the disease.

Central to the success of HIV clinical trials is the principle of collaboration, as researchers, clinicians, community advocates, and affected individuals come together in pursuit of a common goal. Collaborative initiatives such as the HIV Vaccine Trials Network (HVTN) and the AIDS Clinical Trials Group (ACTG) play an important role in coordinating large-scale research efforts, leveraging diverse expertise and resources to accelerate progress. Through shared knowledge, collective effort, and mutual support, these collaborative networks amplify the impact of individual research endeavors, driving meaningful change on a global scale.

However, beyond scientific innovation and collaboration, the true strength of HIV clinical trials lies in their unwavering commitment to prioritizing the voices and experiences of affected communities. Community engagement initiatives ensure that research efforts are culturally sensitive, ethically sound, and grounded in the lived realities of those most impacted by HIV/AIDS. By actively involving community stakeholders in decision-making processes, from trial design to dissemination of findings, researchers cultivate trust, foster empowerment, and promote accountability within affected communities.

Moreover, community-driven research initiatives not only enhance the relevance and effectiveness of interventions but also contribute to the dismantling of structural barriers and systemic inequalities that fuel the HIV epidemic. By centering the needs and perspectives of marginalized populations, including LGBTQ+ individuals, people of color, and those living in resource-limited settings, HIV clinical trials strive to address the root causes of health disparities and promote health equity for all.

As we reflect on the progress made and the challenges that lie ahead, one thing remains clear: the transformative power of HIV clinical trials in shaping the future of HIV/AIDS. By embracing innovation, fostering collaboration, and prioritizing the voices of affected communities, we can accelerate progress towards ending the epidemic and creating a world where HIV/AIDS is a thing of the past. Together, we stand on the brink of a new era in HIV research, where hope triumphs over despair, and the promise of a future free from HIV/AIDS shines brighter than ever before.

POSITIVE SUPPORT FOR FUTURE GENERATION

By Akinremi Simbiat

Mrs. Johnson have been living with HIV for eight years, she discovered her status after her baby boy tested positive at checkup when he was 2 years old. Now her son is almost 10 years, she has been worried about how to inform him of his status and how to ensure that he keep taking his ARVs. Mrs. Johnson confided her fears with the healthcare professional at the facility she receives her ART. The health care professional told her about a program designed especially for Adolescents and young adults, the Operation Triple Zero) program

The Operation Triple Zero (OTZ) program is designed to help make sure HIV Positive Adolescents and Young Persons (AYPs) are virally suppressed. Enrollment into the program starts at age 10; the age group for the program is 10-24 years. When the positive adolescent is 10 years old, the care giver brings the child for enrollment into the program, the child is first asked some questions to determine his/her understanding about HIV and what it entails being positive. If the child doesn’t understand, the care giver is asked to bring the child back when he/she is 12 years old. If the child understands either at 10 years or 12 years, he/she is enrolled into the program.

The child is counseled, taught about HIV, ways to prevent transmission to other people and the importance of adhering to treatment. The child is also advised against disclosing their status especially in school or among their peers so as to prevent stigmatization which could pose a serious burden to them. The OTZ program provides an avenue for HIV positive AYPs to interact freely among themselves, share their concerns, fears and challenges, and also solutions to similar faced problems. They also provide skill acquisitions programs, to better help them be independent and financial stable when they age out of the program. They hold regular meetings either once and twice a month, at this meeting they get their drug refills and viral load checks ensuring privacy from adults and increasing their confidentiality. If an AYPs is discovered to have a high viral load, a fellow member is asked to speak to the individual and ask if he/she have any problems hindering their viral suppression, this proves useful and most AYPs relate better to their age group and take their advice more seriously

Everyone needs a community that understands what you are going through and offers support always, the OTZ program is this for HIV positive adolescents and young persons.

TUBERCULOSIS

By Akinremi Simbiat

Tuberculosis (TB) is a highly contagious bacterial infection that affects the lungs.it is caused by bacterium called mycobacterium tuberculosis; tuberculosis can also affect other organs like the spine, brain and kidney. According to WHO 1.5million people died from the disease in 2020. TB can be spread when a person with active TB disease releases bacteria into the air through coughing, sneezing, talking, singing or even laughing. People nearby who breathe in bacteria can get TB.

If the bacteria survive and multiply in an individual’s lungs, it’s called a TB infection. TB infection maybe in one of four stages with different symptoms for each type.

-Primary TB infection; is the first stage in which the immune system cells finds, captures and fight off the bacteria, but it sometimes doesn’t destroy all of them and the ones that survive multiply.At this stage most people don’t have symptoms or may have flu like symptoms like low fever, tiredness or cough.

-Latent TB infection; is the second stage, at this stage the immune system tries to stop the bacteria from spreading by building a wall around the lung tissue infected with the bacteria. The bacteria may survive but no symptoms is expressed at this stage nor is the infected individual contagious.

Active TB disease; at this stage the immune system cannot control the TB infection. The bacteria can spread throughout the lungs and other parts of the body. Individuals at this stage are usually contagious; they have symptoms like cough, coughing up blood/mucus, chest pain, pain with breathing or coughing, fever chills, night sweats, weight loss, low appetite and tiredness.

-Active TB disease outside the lungs; TB infection can spread to other parts of the body which determine the symptom depending on body part affected. Common symptoms may include fever, chills, night sweats, weight loss, and loss of appetite, tiredness and pain near site of infection.

Other body parts commonly affected by TB diseases outside the lungs are kidneys, liver, fluid surrounding the brain and spinal cord, heart muscles, genitals, lymph nodes, bones and joints, skin, walls of blood vessels and the larynx.

TB can be diagnosed by testing the skin(mantoux tuberculin skin test) or blood(inferferon gamma release assays (IGRAs))or sputumn for a patient coughing for over 2 weeks (Gene Xpert) and also through TB LAM test for HIV positive clients. For confirmation and to determine stage of TB; a chest x-ray or CT scan and Acid fast bacillus tests are also conducted.

Having a weak immune system puts an individual at greater risk of contracting the bacteria, conditions such as diabetes, end stage kidney diseases, malnutrition, long time alcoholic or smoker increases the risk of contracting the bacteria.

HIV weakens the immune system and increases chances of contracting the bacteria, hence most PLHIV contract the  bacteria and develop the disease if they are not cautious or adhere to their HIV medication.

TB is treated in 2 phases: the intensive face which is for 2 months by using drug combination of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide (RHZE); the continuous phase which is for 4 months by using drug combination of Isoniazid and Rifampicin. A final test is usually done at the end of the 6th month to check whether the patient is TB free.

TB is contagious and life threatening but its curable with medication and following recommended healthier lifestyle